Skip to Content
Merck
  • Sensitive ergotamine determination in pharmaceuticals and biological samples using cloud point preconcentration and spectrofluorimetric detection.

Sensitive ergotamine determination in pharmaceuticals and biological samples using cloud point preconcentration and spectrofluorimetric detection.

Analytica chimica acta (2013-03-12)
Chien C Wang, Liliana P Fernández, María Roxana Gómez
ABSTRACT

A new cloud point extraction (CPE) method for ergotamine analysis using fluorimetric detection is described. Ergotamine from an aqueous solution was preconcentrated into a smaller surfactant-rich phase using nonionic surfactant polyoxyethylene(7.5)nonylphenylether (PONPE 7.5). Differently from the conventional CPE procedure in which the resulting surfactant-rich phase is diluted by a fluidificant before its analysis, in this method the fluorescence measurements were carried out directly onto the undiluted surfactant-rich phase. The high viscosity provided by the undiluted surfactant rich phase greatly improved the fluorescence emission of ergotamine, leading to a total enhancement factor of 1325. This spectral advantage plus the preconcentration factor achieved, contributed to the method sensitivity allowing the ergotamine determination at trace level concentration. Under optimal experimental conditions, a linear calibration curve was obtained from 3.81×10(-7) to 1.10μgmL(-1), with detection and quantification limits of 0.11 and 0.38pgmL(-1), respectively. The accuracy and versatility of the present methodology were proved by analyzing ergotamine in real samples of different natures such as pharmaceuticals, urine and saliva.